

# Howard I Scher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5646206/publications.pdf>

Version: 2024-02-01

171  
papers

45,860  
citations

14614

66  
h-index

5663

162  
g-index

178  
all docs

178  
docs citations

178  
times ranked

39528  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2022, 28, 318-326.	3.2	28
2	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 69-79.	0.9	2
3	Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. <i>Journal of Urology</i> , 2022, 207, 1010-1019.	0.2	12
4	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1
5	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
6	Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies. <i>JCO Oncology Practice</i> , 2022, 18, e938-e947.	1.4	5
7	Optimizing the future: how mathematical models inform treatment schedules for cancer. <i>Trends in Cancer</i> , 2022, 8, 506-516.	3.8	14
8	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. <i>Clinical Cancer Research</i> , 2022, 28, 860-869.	3.2	4
9	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
10	Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 831-843.	1.9	2
11	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. <i>Prostate</i> , 2022, , .	1.2	3
12	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
13	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. <i>Science</i> , 2022, 376, .	6.0	75
14	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3603-3617.	3.2	7
15	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38
16	Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. <i>Investigational New Drugs</i> , 2021, 39, 499-508.	1.2	4
17	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. <i>Clinical Cancer Research</i> , 2021, 27, 2050-2060.	3.2	13
18	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup> F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1050-1056.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
20	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	3.6	26
21	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021, 4, 543-552.	2.6	11
22	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	0.8	36
23	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	0.5	11
24	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.2	3
25	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. <i>JAMA Oncology</i> , 2020, 6, e193332.	3.4	39
26	Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling. <i>Clinical Chemistry</i> , 2020, 66, 3-5.	1.5	8
27	Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 170-177.	0.9	60
28	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>JAMA Oncology</i> , 2020, 6, 217.	3.4	18
29	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1167-1179.	1.5	28
30	Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2020, 5, e000943.	2.0	2
31	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	0.9	99
32	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
33	Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 4892-4903.	0.4	26
34	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3230-3238.	3.2	112
35	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 507-516.	2.0	10
36	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 171-178.e2.	0.9	25

#	ARTICLE	IF	CITATIONS
37	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
38	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020, 78, 671-679.	0.9	72
39	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020, 4, 355-366.	1.5	93
40	<i>PTEN</i> Loss with <i>ERG</i> Negative Status is Associated with Lethal Disease after Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 203, 344-350.	0.2	12
41	Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer. <i>Journal of Circulating Biomarkers</i> , 2020, 9, 13-19.	0.8	7
42	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2184-2186.	0.8	7
43	The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. <i>Cancer Cell</i> , 2019, 36, 139-155.e10.	7.7	131
44	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	13.7	295
45	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>European Urology Oncology</i> , 2019, 2, 605-616.	2.6	30
46	Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test – In Reply. <i>JAMA Oncology</i> , 2019, 5, 434.	3.4	0
47	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup> Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1517-1523.	2.8	38
48	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	3.3	839
49	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	0.8	267
50	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 43-51.	3.2	177
51	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	3.4	426
52	Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. <i>Clinical Chemistry</i> , 2019, 65, 87-99.	1.5	109
53	Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 338-348.	1.2	7
54	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702

#	ARTICLE	IF	CITATIONS
55	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019, 75, 929-937.	0.9	41
56	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 458-467.	1.2	61
57	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
58	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018, 9, 1629.	5.8	37
59	Reproducibility and Repeatability of Semiquantitative <sup>18</sup> F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1516-1523.	2.8	20
60	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018, 50, 645-651.	9.4	601
61	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 168-182.	12.5	7
62	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	3.4	93
63	Reply to C. Ren et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2354-2356.	0.8	0
64	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
65	Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). <i>British Journal of Cancer</i> , 2018, 119, 1041-1043.	2.9	4
66	Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1179.	3.4	190
67	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-580.	0.8	187
68	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1344.	3.4	169
69	Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 198, 65-70.	0.2	32
70	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
71	Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1673.	3.4	1
72	Author Reply. <i>Urology</i> , 2017, 102, 172.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 874-882.	0.9	150
74	Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 5687-5698.	0.4	112
75	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , 2017, 32, 792-806.e7.	7.7	61
76	Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. <i>European Urology</i> , 2017, 71, 4-6.	0.9	24
77	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. <i>Clinical Cancer Research</i> , 2017, 23, 1967-1973.	3.2	46
78	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	0.5	52
79	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	286
80	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	13.9	1,205
81	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016, 8, 367ra167.	5.8	23
82	Defining new standards of care for men with prostate cancer. <i>Lancet</i> , The, 2016, 387, 1135-1137.	6.3	1
83	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Targeted Axis Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 73S-78S.	2.8	16
84	First-in-Human Imaging with <sup>89</sup> Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	2.8	116
85	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e15-530.e21.	0.8	38
86	Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1441.	3.4	535
87	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1510-1519.	3.2	117
88	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-565.	0.8	1,746
89	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
90	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. <i>Cancer</i> , 2015, 121, 3853-3861.	2.0	27

#	ARTICLE	IF	CITATIONS
91	Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. <i>PLoS ONE</i> , 2015, 10, e0139440.	1.1	181
92	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
93	CHAARTED/GETUG 12â€”docetaxel in non-castrate prostate cancers. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 687-688.	12.5	4
94	Long-term Safety and Antitumor Activity in the Phase 1â€”2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2015, 68, 795-801.	0.9	39
95	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	0.8	120
96	A window into new drug development for urologic oncology. Part II: Bench-to bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 269.	0.8	0
97	A window into new drug development for urologic oncology. Part I: How bench-to bedside research can result in approval. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 115.	0.8	0
98	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
99	Biomarker development in the context of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 295-301.	0.8	20
100	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	3.2	163
101	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e305-e309.	0.9	30
102	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. <i>EJNMMI Research</i> , 2015, 5, 28.	1.1	63
103	Feedback Suppression of PI3KÎ± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3KÎ². <i>Cancer Cell</i> , 2015, 27, 109-122.	7.7	203
104	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
105	Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 147-147.	0.8	3
106	Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, 169-169.	0.8	2
107	Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e204-e212.	1.8	2
108	Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3082-3096.	2.5	27

#	ARTICLE	IF	CITATIONS
109	High-risk prostate cancerâ€”classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 308-323.	12.5	340
110	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	13.5	1,184
111	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	13.9	2,456
112	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	5.1	1,280
113	Analytic and Clinical Validation of a Prostate Cancerâ€”Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. <i>European Urology</i> , 2014, 65, 1191-1197.	0.9	66
114	Validation and clinical utility of prostate cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 225-234.	12.5	83
115	Phase II Study of Lutetium-177â€”Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5182-5191.	3.2	370
116	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 1187-1197.	13.9	3,847
117	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	5.1	254
118	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 25-25.	0.8	11
119	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA1-LBA1.	0.8	66
120	Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics. <i>Clinical Cancer Research</i> , 2011, 17, 6634-6640.	3.2	46
121	Integrative Genomic Profiling of Human Prostate Cancer. <i>Cancer Cell</i> , 2010, 18, 11-22.	7.7	3,151
122	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â€”2 study. <i>Lancet</i> , The, 2010, 375, 1437-1446.	6.3	972
123	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. <i>Lancet Oncology</i> , The, 2009, 10, 233-239.	5.1	558
124	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	0.8	1,960
125	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6302-6309.	3.2	1,975
126	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2707-2713.	3.2	73



#	ARTICLE	IF	CITATIONS
127	The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1488-1492.	3.2	67
128	Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards. <i>Clinical Cancer Research</i> , 2005, 11, 5223-5232.	3.2	126
129	Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. <i>Journal of Clinical Oncology</i> , 2005, 23, 8253-8261.	0.8	932
130	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2004, 11, 459-476.	1.6	212
131	Current management of hormone-refractory prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 724-6.	0.3	1
132	Prostate carcinoma. <i>Cancer</i> , 2003, 97, 758-771.	2.0	45
133	HER-2 profiling and targeting in prostate carcinoma. <i>Cancer</i> , 2002, 94, 980-986.	2.0	128
134	HER-2 profiling and targeting in prostate carcinoma. , 2002, 94, 980.		1
135	Picking the winners in a sea of plenty. <i>Clinical Cancer Research</i> , 2002, 8, 400-4.	3.2	14
136	The collection of indirect and nonmedical direct costs (COIN) form. <i>Cancer</i> , 2001, 91, 841-853.	2.0	31
137	The collection of indirect and nonmedical direct costs (COIN) form. <i>Cancer</i> , 2001, 91, 841-853.	2.0	1
138	Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. <i>Cancer</i> , 2000, 88, 1671-1678.	2.0	112
139	Identification and characterization of circulating prostate carcinoma cells. <i>Cancer</i> , 2000, 88, 2787-2795.	2.0	82
140	Novel strategies and therapeutics for the treatment of prostate carcinoma. <i>Cancer</i> , 2000, 89, 1329-1348.	2.0	48
141	A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 79-83.	1.1	15
142	Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 1936-1941.	0.8	64
143	Identification and characterization of circulating prostate carcinoma cells. , 2000, 88, 2787.		1
144	Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2546-2546.	0.8	152

#	ARTICLE	IF	CITATIONS
145	A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle. <i>Angewandte Chemie - International Edition</i> , 1999, 38, 563-566.	7.2	87
146	Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy. <i>Journal of Clinical Oncology</i> , 1999, 17, 3173-3181.	0.8	658
147	Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. <i>Nature Medicine</i> , 1998, 4, 50-57.	15.2	249
148	Rapid screening for psychologic distress in men with prostate carcinoma. , 1998, 82, 1904-1908.		867
149	Detectable tumor cells in the blood and bone marrow. , 1998, 83, 394-398.		10
150	Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. , 1998, 7, 129-132.		40
151	INTERSTITIAL PNEUMONITIS FOLLOWING BICALUTAMIDE TREATMENT FOR PROSTATE CANCER. <i>Journal of Urology</i> , 1998, 160, 131-131.	0.2	11
152	Rapid screening for psychologic distress in men with prostate carcinoma. , 1998, 82, 1904.		4
153	Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. , 1998, 7, 129.		19
154	Intracavitary birdcage resonator: Applications to the human prostate. <i>Journal of Magnetic Resonance Imaging</i> , 1995, 5, 365-368.	1.9	0
155	Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. <i>Cancer</i> , 1994, 73, 2791-2802.	2.0	320
156	Expression of Transforming Growth Factor- $\beta$ and the Epidermal Growth Factor Receptor in Human Prostate Tissues. <i>Journal of Urology</i> , 1994, 152, 2120-2124.	0.2	89
157	Immune-mediated thrombocytopenia secondary to suramin. <i>Cancer</i> , 1993, 71, 851-854.	2.0	14
158	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317.	2.0	26
159	Chemotherapy for urothelial tract malignancies: Breaking the deadlock. <i>Journal of Surgical Oncology</i> , 1992, 8, 316-341.	1.4	40
160	Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor: A possible new recombinant granulocyte colony-stimulating factor toxicity. <i>Cancer</i> , 1992, 70, 2699-2702.	2.0	64
161	Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. <i>Cancer</i> , 1992, 70, 2870-2878.	2.0	44
162	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470.	2.0	37

#	ARTICLE	IF	CITATIONS
163	Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. <i>Cancer</i> , 1989, 64, 2448-2458.	2.0	654
164	M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium. <i>Journal of Urology</i> , 1988, 139, 461-469.	0.2	517
165	Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder Lesion. <i>Journal of Urology</i> , 1988, 139, 470-474.	0.2	211
166	Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Extravesical Urinary Tract Tumors. <i>Journal of Urology</i> , 1988, 139, 475-477.	0.2	48
167	Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 24-26.	1.1	21
168	Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium. <i>Journal of Urology</i> , 1985, 133, 403-407.	0.2	630
169	Experimental Studies and Phase II Trial of Bisantrene in Advanced Urothelial Malignancies. <i>Cancer Investigation</i> , 1985, 3, 123-127.	0.6	6
170	Controversies in Treatment of Small Cell Carcinoma of the Lung. <i>Cancer Investigation</i> , 1985, 3, 367-387.	0.6	17
171	Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in phase II trial of flutamide. <i>Cancer</i> , 1984, 54, 477-481.	2.0	22